SC
ATOS icon

Sculptor Capital’s Atossa Therapeutics ATOS Stock Holding History

Sculptor Capital’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,300
Closed -$343K – 1225
2021
Q4 		$343K Hold
14,300
– – ﹤0.01% 788
2021
Q3 		$699K Sell
14,300
-3,567
-20% -$207K 0.01% 617
2021
Q2 		$1.69M Buy
17,867
+14,300
+401% +$757K 0.01% 545
2021
Q1 		$113K Buy
+3,567
New +$130K ﹤0.01% 623

Other funds holding ATOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sculptor Capital's ATOS Position: Q1 2022 in Review

Sculptor Capital sold out of Atossa Therapeutics (ATOS) in Q1 2022, closing a stake of 14,300 shares — an estimated $343K sold.

Sculptor Capital first reported a position in ATOS in Q1 2021 and held it in 4 quarters. The position peaked at $1.69M in Q2 2021. 83 funds tracked by Wall St. Rank hold ATOS as of Q1 2022.

  • Sculptor Capital reported no remaining Atossa Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sculptor Capital sold 14,300 Atossa Therapeutics shares in Q1 2022, an estimated $343K.
  • Sculptor Capital first reported a position in Atossa Therapeutics in Q1 2021 and held it in 4 quarters.
  • Sculptor Capital's Atossa Therapeutics position peaked at $1.69M in Q2 2021.
  • 83 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2022.

Based on Sculptor Capital's 13F filing for Q1 2022, filed 13 May 2022.